ArticleBiotechnology for biofuels2016
Metabolic engineering of Bacillus subtilis for chiral pure meso-2,3-butanediol production.
Article in Biotechnology for biofuels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 106 citations in OpenAlex.
- Enhanced production of l-histidine inSynthetic and systems biotechnology · 2026Article
- Engineering of Corynebacterium glutamicum for the enhanced production of optically pure (meso)-2,3-butanediol.Bioresources and bioprocessing · 2026Article
- Efficient 2,3-Butanediol Production from Ethanol by a Modified Four-Enzyme Synthetic Biosystem.Molecules (Basel, Switzerland) · 2024Article
- Mechanism of microbial production of acetoin and 2,3-butanediol optical isomers and substrate specificity of butanediol dehydrogenase.Microbial cell factories · 2023Review
- Investigation of two metabolic engineering approaches for (R,R)-2,3-butanediol production from glycerol in Bacillus subtilis.Journal of biological engineering · 2023Article
- Metabolic engineering for the production of acetoin and 2,3-butanediol at elevated temperature inFrontiers in bioengineering and biotechnology · 2023Article
- Review
- Development of an industrial yeast strain for efficient production of 2,3-butanediol.Microbial cell factories · 2022Article
- Metabolic engineering of Corynebacterium glutamicum for efficient production of optically pure (2R,3R)-2,3-butanediol.Microbial cell factories · 2022Article
- Enhancing the capability of Klebsiella pneumoniae to produce 1, 3-propanediol by overexpression and regulation through CRISPR-dCas9.Microbial biotechnology · 2022Article
- Regulatory role of cysteines in (2R, 3R)-butanediol dehydrogenase BdhA of Bacillus velezensis strain GH1-13.Journal of microbiology (Seoul, Korea) · 2022Article
- Blocking the 2,3-butanediol synthesis pathway of Klebsiella pneumoniae resulted in L-valine production.World journal of microbiology & biotechnology · 2022Article
- Bioengineering for the industrial production of 2,3-butanediol by the yeast, Saccharomyces cerevisiae.World journal of microbiology & biotechnology · 2022Review
- Enhanced production of iturin A by strengthening fatty acid synthesis modules inFrontiers in bioengineering and biotechnology · 2022Article
- Identification and Characterization of a Novel Soluble Pyridine Nucleotide Transhydrogenase from Streptomyces avermitilis.Current microbiology · 2021Article
- Metabolic Engineering of Central Carbon Metabolism of Bacillus licheniformis for Enhanced Production of Poly-γ-glutamic Acid.Applied biochemistry and biotechnology · 2021Article
- Metabolic engineering design to enhance (R,R)-2,3-butanediol production from glycerol in Bacillus subtilis based on flux balance analysis.Microbial cell factories · 2021Article
- Increasing ATP turnover boosts productivity of 2,3-butanediol synthesis in Escherichia coli.Microbial cell factories · 2021Article
- Process optimization for mass production of 2,3-butanediol by Bacillus subtilis CS13.Biotechnology for biofuels · 2021Article
- Rational Proteomic Analysis of a New DomesticatedFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background2,3-Butanediol (2,3-BD) with low toxicity to microbes, could be a promising alternative for biofuel production. However, most of the 2,3-BD producers are opportunistic pathogens that are not suitable for industrial-scale fermentation. In our previous study, wild-type Bacillus subtilis 168, as a class I microorganism, was first found to generate only d-(-)-2,3-BD (purity >99 %) under low oxygen conditions.
resultsIn this work, B. subtilis was engineered to produce chiral pure meso-2,3-BD. First, d-(-)-2,3-BD production was abolished by deleting d-(-)-2,3-BD dehydrogenase coding gene bdhA, and acoA gene was knocked out to prevent the degradation of acetoin (AC), the immediate precursor of 2,3-BD. Next, both pta and ldh gene were deleted to decrease the accumulation of the byproducts, acetate and l-lactate. We further introduced the meso-2,3-BD dehydrogenase coding gene budC from Klebsiella pneumoniae CICC10011, as well as overexpressed alsSD in the tetra-mutant (ΔacoAΔbdhAΔptaΔldh) to achieve the efficient production of chiral meso-2,3-BD. Finally, the pool of NADH availability was further increased to facilitate the conversion of meso-2,3-BD from AC by overexpressing udhA gene (coding a soluble transhydrogenase) and low dissolved oxygen control during the cultivation. Under microaerobic oxygen conditions, the best strain BSF9 produced 103.7 g/L meso-2,3-BD with a yield of 0.487 g/g glucose in the 5-L batch fermenter, and the titer of the main byproduct AC was no more than 1.1 g/L.
conclusionThis work offered a novel strategy for the production of chiral pure meso-2,3-BD in B. subtilis. To our knowledge, this is the first report indicating that metabolic engineered B. subtilis could produce chiral meso-2,3-BD with high purity under limited oxygen conditions. These results further demonstrated that B. subtilis as a class I microorganism is a competitive industrial-level meso-2,3-BD producer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.